Vitalnext
Developer of a powdered food for special medical purposes formulated to address disease-related malnutrition and loss of muscle mass/function. The product was developed using preclinical models and randomized clinical studies in collaboration with research partners, complies with EU guidelines for medical nutrition, and is supplied via prescription and clinical channels.
Industries
Nr. of Employees
small (1-50)
Vitalnext
J.H. Oortweg 19, 2333 CH Leiden, The Netherlands
Patents
Products
VitalNext (powdered medical nutrition sachets)
A powdered food for special medical purposes supplied in 63 g sachets (10 sachets per box), formulated to be mixed with a variety of foods and drinks to address disease-related malnutrition and loss of muscle mass/function.
VitalNext (powdered medical nutrition sachets)
A powdered food for special medical purposes supplied in 63 g sachets (10 sachets per box), formulated to be mixed with a variety of foods and drinks to address disease-related malnutrition and loss of muscle mass/function.
Services
Information and materials for healthcare professionals on prescribing the powdered medical nutrition and integrating it into patient care.
Information and materials for healthcare professionals on prescribing the powdered medical nutrition and integrating it into patient care.
Expertise Areas
- Medical nutrition formulation
- Clinical trial execution and evaluation
- Preclinical efficacy testing
- Regulatory compliance for foods for special medical purposes (EU)
Key Technologies
- Powdered oral nutritional formulation
- Whey/casein protein blend formulation
- Branched-chain amino acid supplementation
- Inclusion of bioactive small molecules (ursolic acid)
News & Updates
Preclinical study reporting prevention of muscle loss and accelerated muscle mass recovery in caloric-restricted mice (Metabolism, 2019).
Randomized controlled trial reporting improved gait speed and mitochondrial function in older adults compared to standard care (Aging, 2021).
Closed a Series B financing round with participation from existing investors to support the market launch and international expansion of the medical nutrition product.
Preclinical study reporting prevention of muscle loss and accelerated muscle mass recovery in caloric-restricted mice (Metabolism, 2019).
Randomized controlled trial reporting improved gait speed and mitochondrial function in older adults compared to standard care (Aging, 2021).
Closed a Series B financing round with participation from existing investors to support the market launch and international expansion of the medical nutrition product.